KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).

Jürgen Finke, Claudia Schmoor, Francis Ayuk, Justin Hasenkamp, Mareike Verbeek, Eva-Maria Wagner, Harald Biersack, Kerstin Schäfer-Eckart, Dominik Wolf, Gernot Stuhler, Roland Reibke, Christoph Schmid, Martin Kaufmann, Matthias Eder, Hartmut Bertz, Olga Grishina

Bone Marrow Transplant 59(7) 936-941

PMID38493275
PMCIDPMC11226393
DOI10.1038/s41409-024-02264-9
发表日期2024-03-17
入排依据:This record is for a non-randomized, observational study (ATOS) that compares its results to a previously reported Phase III randomized trial. It is not an original report of the randomized trial's results.
摘要

摘要

ATOS is a prospective observational study evaluating the outcome of patients receiving anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation. Primary endpoint was severe GvHD and relapse-free survival (SGRFS). GvHD prophylaxis consisted of ATLG and CSA/ MTX or MMF. Outcome was compared to the ATLG arm of our prospective randomized phase III multicenter trial trial (RCT) [1, 2]. 165 patients, median age 54 (18; 77) years, with haematological malignancies with early (45.5%), intermediate (17.6%), and advanced (37.0%) disease were included. ATLG dose differed between centers according to local practise (median total ATLG dose of 46 (IQR 32-60, range 15-91) mg/kg). Median follow-up was 70 months. Estimated probabilities at 5 years follow up were for SGRFS 0.27, OS 0.52, DFS 0.43, NRM 0.23, relapse 0.34, acute GvhD °III/IV 0.13, severe chronic GvHD 0.27. OS rates differed dependent on disease status. An effect of the given ATLG dose could not be separated from potential center effects. Despite higher age and more advanced disease in ATOS, outcome was similar to the ATLG arm of our RCT. This long-term, multicenter, experience in routine clinical practice confirms the GvHD-protective effect of ATLG without compromising relapse and non-relapse mortality rates.Clinical Trial Registry: German clinical trials register DRKS00004581.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。